Non-vitamin K antagonist oral anticoagulants in adults with a Fontan circulation: are they safe [PDF]
Open Heart, 2019 Background In Fontan patients with atrial arrhythmias (AA), non-vitamin K antagonist oral anticoagulants(NOACs) have a class III recommendation according to the Pediatric & Congenital Electrophysiology Society (PACES)/Heart Rhythm Society (HRS) guideline in 2014, due to lack of data on outcomes as opposed to ...
Yang, Hayang +18 more
core +14 more sources
Non-vitamin K antagonist oral anticoagulants and antiphospholipid syndrome [PDF]
Rheumatology, 2016 The current treatment of thrombotic APS patients includes long-term anticoagulation with oral vitamin K antagonists (VKAs), with warfarin being the one most commonly used. However, the use of VKAs can be challenging, especially in patients with APS.
Sciascia, Savino +5 more
core +6 more sources
Non-vitamin K antagonist oral anticoagulants and sport
Minerva Cardioangiologica, 2020 Physical activity is worldwide recommended for its benefits on cardiovascular system. There is an increasing number of people of all ages that approach sport activity both as leisure time physical activity and as competitive sport. It is always more frequent the request even from older subjects and cardiac patients to be allowed to practice physical ...
Romano S. +5 more
openaire +3 more sources
Non–Vitamin K Antagonist Oral Anticoagulants in Coronary Artery Disease
Hämostaseologie, 2021 AbstractThe prevention of atherothrombotic events is the primary goal in the treatment of patients with arteriosclerotic disorders. Despite recent improvements in the management of coronary artery disease (CAD) with revascularization techniques and antiplatelet therapy, some patients remain at risk of recurrent cardiovascular events.
Samer, Al Said +3 more
openaire +3 more sources
An Update on the Reversal of Non-Vitamin K Antagonist Oral Anticoagulants
Advances in Hematology, 2020 Non-vitamin K antagonist oral anticoagulants (NOACs) include thrombin inhibitor dabigatran and coagulation factor Xa inhibitors rivaroxaban, apixaban, edoxaban, and betrixaban.
Mark Terence P. Mujer +7 more
doaj +4 more sources
Changes in primary care management of atrial fibrillation patients following the shift from warfarin to non-vitamin K antagonist oral anticoagulants: a Norwegian population based study [PDF]
BMC Primary Care, 2022 Background To assess baseline characteristics, drug utilisation and healthcare use for oral anticoagulants (OACs) following the introduction of non-vitamin K antagonist oral anticoagulants among patients with atrial fibrillation in primary care in Norway.
Sigrun Halvorsen +6 more
doaj +2 more sources
Non-Vitamin K Antagonist Oral Anticoagulants in Patients with β-Thalassemia
Biology, 2023 Background. Patients with β-thalassemia have a high incidence of atrial fibrillation (AF) and other supraventricular arrhythmias. The use of non-vitamin K antagonist oral anticoagulants (NOACs) for thromboembolic prophylaxis in patients with β ...
Michele Malagù +8 more
doaj +3 more sources
Data on incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants [PDF]
Data in Brief, 2018 This article contains the data showing the different characteristics of atrial fibrillation (AF) patients treated with vitamin K (VKAs) or non-vitamin K antagonist oral anticoagulants (NOACs) screened for the presence of liver fibrosis (LF) and followed ...
Daniele Pastori +9 more
doaj +2 more sources
Comparison of ََQuality of Life and Treatment Satisfaction among Sample of Iraqi Patients Using Anticoagulant Therapy (Warfarin or Non-Vitamin K Antagonist Oral Anticoagulants) [PDF]
مجلة كلية الطبBackground: Oral anticoagulation medication, warfarin and non-vitamin k antagonist oral anticoagulants (NOAC) may require long term use which may affect patients’ satisfaction with their treatment and their quality of life (QOL). Objective: To compare
Basma Z. Al-Metwali, Tuqa M. AL-Ameen
doaj +2 more sources
Inclusion in the World Health Organization Model List of Essential Medicines of Non-Vitamin K Anticoagulants for Treatment of Non-Valvular Atrial Fibrillation: A Step Towards Reducing the Burden of Cardiovascular Morbidity and Mortality [PDF]
Global Heart, 2020 Non-vitamin K antagonist oral anticoagulants (NOACs) represent a paradigm shift in the treatment of non-valvular atrial fibrillation (AF) with major practice guidelines around the world recommending NOACs over vitamin K antagonist oral anticoagulants for
Ezequiel J. Zaidel +10 more
doaj +2 more sources